EMA Authorised: Ogsiveo (nirogacestat hydrobromide) — Merck Europe B.V.

View source ↗

Summary

Marketing authorization has been granted for Ogsiveo (nirogacestat hydrobromide) by EMA for desmoid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Desmoid Tumor

Drugs mentioned

• OGSIVEO (NIROGACESTAT)

Snippet

Status: Authorised. Therapeutic area: Desmoid Tumors. MAH: Merck Europe B.V.. Decision date: 02/07/2026. Orphan medicine